Antagonists of the beta-adrenergic receptor (β-AR antagonists) are a heterogeneous class
of drugs. Selected members of this class are highly recommended in congestive heart failure …

Background Safety concerns regarding long-acting β2-agonists (LABAs) in asthma
management were initially identified in a large postmarketing trial in which the risk of death …

In vitro data suggest that salmeterol, contrary to formoterol, can partly antagonise the effect
of short-acting β2-agonist rescue medication. To explore whether this occurs in vivo, we …

Background Salmeterol is the first long-acting inhaled bronchodilator available in the United
States. This paper summarizes the combined results of the two pivotal US studies evaluating …

Inhaled β-adrenergic agonist bronchodilators are integral components of effective asthma
treatment. However, the risk of asthma morbidity and mortality associated with the regular …

According to major asthma management guidelines, long-acting β2-agonists (LABAs)
should be used only when asthma remains symptomatic in patients already receiving …

Previous results have demonstrated addition of long-acting β2-adrenergic agonists to be
beneficial in asthma patients already receiving inhaled corticosteroid. The purpose of this …

The quote from Shakespeare's Macbeth,''Double, double toil and trouble;/Fire burn, and
cauldron bubble,''captures the quagmire faced by many clinicians today when deciding on …

Scheduled chronic administration of β 2-adrenoceptor agonist bronchodilators in patients
with asthma recently has been reported to be associated with a worsening of symptoms and …